US Pharm. 2012;37(4):1.
Abbott Park, IL—Abbott Laboratories has announced that
its pharmaceutical division will be known as AbbVie by late 2012. It
will be a separate, publicly traded company from its parent. Drugs
include the top-selling Humira for arthritis, Lupron for prostate
cancer, and Synagis for respiratory virus. Richard A. Gonzalez,
currently executive vice president, Global Pharmaceuticals, has been
named CEO of the new company. Abbott Laboratories will retain its name
and focus on nutritional products, branded generics, and medical
devices. AbbVie will be located at Abbott’s campus near Chicago and will
account for approximately 45% of the company’s revenue.
To comment on this article, contact email@example.com.
U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date,
authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings,
including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations,
long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students,
other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn
Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE)
as a provider of continuing pharmacy education.
Copyright © 2000 - 2013 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.